Therapeutic interventions targeting CD40L (CD154) and CD40: the opportunities and challenges - PubMed (original) (raw)

Review

Therapeutic interventions targeting CD40L (CD154) and CD40: the opportunities and challenges

Che-Leung Law et al. Adv Exp Med Biol. 2009.

Abstract

CD40 was originally identified as a receptor on B-cells that delivers contact-dependent T helper signals to B-cells through interaction with CD40 ligand (CD40L, CD154). The pivotal role played by CD40-CD40L interaction is illustrated by the defects in B-lineage cell development and the altered structures of secondary lymphoid tissues in patients and engineered mice deficient in CD40 or CD40L. CD40 signaling also provides critical functions in stimulating antigen presentation, priming of helper and cytotoxic T-cells and a variety of inflammatory reactions. As such, dysregulations in the CD40-CD40L costimulation pathway are prominently featured in human diseases ranging from inflammatory conditions to systemic autoimmunity and tissue-specific autoimmune diseases. Moreover, studies in CD40-expressing cancers have provided convincing evidence that the CD40-CD40L pathway regulates survival of neoplastic cells as well as presentation of tumor-associated antigens to the immune system. Extensive research has been devoted to explore CD40 and CD40L as drug targets. A number of anti-CD40L and anti-CD40 antibodies with diverse biological effects are in clinical development for treatment of cancer and autoimmune diseases. This chapter reviews the role of CD40-CD40L costimulation in disease pathogenesis, the characteristics of therapeutic agents targeting this pathway and status of their clinical development.

PubMed Disclaimer

Similar articles

• Mechanistic basis of co-stimulatory CD40-CD40L ligation mediated regulation of immune responses in cancer and autoimmune disorders.
  Chand Dakal T, Dhabhai B, Agarwal D, Gupta R, Nagda G, Meena AR, Dhakar R, Menon A, Mathur R, Mona, Yadav V, Sharma A. Chand Dakal T, et al. Immunobiology. 2020 Mar;225(2):151899. doi: 10.1016/j.imbio.2019.151899. Epub 2019 Dec 17. Immunobiology. 2020. PMID: 31899051 Review.
• Autoimmune thrombocytopenia: flow cytometric determination of platelet-associated CD154/CD40L and CD40 on peripheral blood T and B lymphocytes.
  Meabed MH, Taha GM, Mohamed SO, El-Hadidy KS. Meabed MH, et al. Hematology. 2007 Aug;12(4):301-7. doi: 10.1080/10245330701383957. Hematology. 2007. PMID: 17654056
• The role of CD40-CD154 interactions in autoimmunity and the benefit of disrupting this pathway.
  Toubi E, Shoenfeld Y. Toubi E, et al. Autoimmunity. 2004 Sep-Nov;37(6-7):457-64. doi: 10.1080/08916930400002386. Autoimmunity. 2004. PMID: 15621572 Review.
• Influenza-induced, helper-independent CD8+ T cell responses use CD40 costimulation at the late phase of the primary response.
  Seah SG, Brady JL, Carrington EM, Ng WC, Sutherland RM, Hancock MS, La Gruta NL, Brown LE, Turner SJ, Lew AM, Zhan Y. Seah SG, et al. J Leukoc Biol. 2013 Jan;93(1):145-54. doi: 10.1189/jlb.0612266. Epub 2012 Oct 29. J Leukoc Biol. 2013. PMID: 23108101
• Different costimulation signals used by CD4(+) and CD8(+) cells that independently initiate rejection of allogenic hepatocytes in mice.
  Gao D, Li J, Orosz CG, Bumgardner GL. Gao D, et al. Hepatology. 2000 Nov;32(5):1018-28. doi: 10.1053/jhep.2000.19325. Hepatology. 2000. PMID: 11050052

Cited by

• Targeting the TNF and TNFR superfamilies in autoimmune disease and cancer.
  Croft M, Salek-Ardakani S, Ware CF. Croft M, et al. Nat Rev Drug Discov. 2024 Dec;23(12):939-961. doi: 10.1038/s41573-024-01053-9. Epub 2024 Oct 24. Nat Rev Drug Discov. 2024. PMID: 39448880 Review.
• Galectin-9 controls CD40 signaling through a Tim-3 independent mechanism and redirects the cytokine profile of pathogenic T cells in autoimmunity.
  Vaitaitis GM, Wagner DH Jr. Vaitaitis GM, et al. PLoS One. 2012;7(6):e38708. doi: 10.1371/journal.pone.0038708. Epub 2012 Jun 7. PLoS One. 2012. PMID: 22685601 Free PMC article.
• Expression, purification and biological characterization of the extracellular domain of CD40 from Pichia pastoris.
  Zhan Y, Wei Y, Chen P, Zhang H, Liu D, Zhang J, Liu R, Chen R, Zhang J, Mo W, Zhang X. Zhan Y, et al. BMC Biotechnol. 2016 Jan 25;16:8. doi: 10.1186/s12896-016-0237-1. BMC Biotechnol. 2016. PMID: 26809818 Free PMC article.
• Innovative Therapeutic Approaches in Primary Cutaneous B Cell Lymphoma.
  Lang CCV, Ramelyte E, Dummer R. Lang CCV, et al. Front Oncol. 2020 Aug 7;10:1163. doi: 10.3389/fonc.2020.01163. eCollection 2020. Front Oncol. 2020. PMID: 32850331 Free PMC article. Review.
• Clinical targeting of the TNF and TNFR superfamilies.
  Croft M, Benedict CA, Ware CF. Croft M, et al. Nat Rev Drug Discov. 2013 Feb;12(2):147-68. doi: 10.1038/nrd3930. Epub 2013 Jan 21. Nat Rev Drug Discov. 2013. PMID: 23334208 Free PMC article. Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Springer

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information

• Research Materials

  • NCI CPTC Antibody Characterization Program